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Objectives: To estimate the number and cost of asthma-related productivity loss days due to 
absenteeism and presenteeism (at work but not fully functioning) in Alberta in 2005.
Methods: Using data from the 2005 Canadian Community Health Survey, this study focused 
on people of working age (18–64 years), who reported having an asthma diagnosis. Total 
asthma-related disability days, including in-bed days and activity-restricted days, were esti-
mated by multiplying the difference in the means of total disability days between asthmatics 
and nonasthmatics adjusted for sociodemographic characteristics and other health conditions 
by a multiple linear regression, with the number of asthmatics in the population. Number of 
productivity loss days was a sum between the number of in-bed days (absenteeism) and the 
number of activity-restricted days multiplied by a reduction in functional level (presenteeism), 
adjusted for ﬁ  ve working days per week. Other data from Alberta or Canadian published lit-
erature, such as a reduction in functional level of 20%–30%, a labor participation rate of 73%, 
and an average wage of $158 per day in 2005, were also used for analyses.
Results: The prevalence of asthma was estimated at 8.5% among approximately 2.1 million 
people of working age in Alberta in 2005. The difference in the means of total disability days 
between asthmatics and nonasthmatics was 0.487 (95% CI: 0.286–0.688) in a period of two weeks 
or 12.7 (7.5–17.9) in one year. With the reduction in functional level of 20%–30%, the number 
of asthma-related productivity loss days was estimated from 442 (259–624) to 533 (313–753) 
thousand, respectively. The corresponding cost was from $70 ($41–$99) to $84 ($49–$119) 
million. Of these, the presenteeism accounted for 42% to 52%.
Conclusions: The results suggest that an improvement in the controlling of asthma could 
have a signiﬁ  cant economic impact in Alberta and that presenteeism plays an important role 
in asthma-related productivity losses and therefore employers should not only pay attention to 
absenteeism, but also to presenteeism to minimize productivity loss.
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Introduction
Asthma is a chronic inﬂ  ammatory disorder associated with airway hyper-responsiveness 
to stimulus that leads to recurrent episodes of wheezing, breathlessness, chest tightness, 
and coughing. These episodes are usually associated with widespread, but variable, 
airﬂ  ow obstruction within the lung that is often reversible either spontaneously or with 
treatment.1,2
In Canada, it is estimated that currently over three million people have asthma. 
According to Statistics Canada, 8.3% of the population aged 12 and older have been 
diagnosed at some time as having asthma.3 About 500 adults die from asthma each year.4 
The economic burden of asthma is considerable both in terms of direct medical costs 
and indirect costs due to productivity losses. According to Health Canada,5 an economic 
burden of over $4 billion can be attributed to asthma, bronchitis and emphysema in 
1998. Of this, indirect costs accounted for 53%. The costs of hospitalization and drugs 
for asthma alone were $102 million and 301 million in 1998, respectively.5Journal of Asthma and Allergy 2009:2 44
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In another study,6 Krahn and colleagues estimated that 
the annual cost of asthma in Canada was from $504 to 
$648 million in 1990. Of this, indirect costs accounted for 
39%. In southern Ontario, asthma cost per patient per year 
was estimated at $2,550 in 2005 with indirect costs account-
ing for 50%.7
In Alberta, it was estimated that the direct cost of asthma 
from a societal perspective was more than $65 million in 
2006.8
Although the indirect costs account for a large share of 
the total cost, there is no Alberta-based study on indirect 
costs of asthma. The indirect costs mainly refer to produc-
tivity losses due to absenteeism (absent from work) and 
presenteeism (at work but not fully functioning). Though it 
can be costlier than absenteeism, presenteeism is not always 
apparent.9 This study aims to estimate the number and cost 
of asthma-related productivity loss days due to absenteeism 
and presenteeism in Alberta.
Methods
The 2005 Canadian Community Health Survey (CCHS) was 
a cross-sectional survey, done by Statistics Canada, to collect 
information related to health status, health care utilization and 
health determinants for the Canadian population. The 2005 
CCHS targeted people aged 12 years and older who live in 
private dwellings in 125 health regions in all provinces and 
territories of Canada. Using a multistage stratiﬁ  ed cluster 
design, the survey included 132,221 people representing a 
population of 27,126,165. The corresponding numbers for 
province of Alberta were 11,800 and 2,686,119, respectively. 
The CCHS is well-known and validated and details have been 
published elsewhere.10
Using Alberta’s data from the 2005 CCHS, this study 
focused on people of working age (18–64 years) who reported 
having an asthma diagnosis. We used a societal perspective 
with a one-year time horizon.
Total asthma-related disability days were estimated by 
multiplying the difference in the means of total disabil-
ity days between asthmatics and nonasthmatics with the 
number of asthmatics in the population. A multiple linear 
regression was used to adjust the difference for sociode-
mographic characteristics and other health conditions of 
the people as shown in Table 1. These covariates were 
chosen based on the potential associations between them 
and disability days, and asthma; and on the availability 
in the dataset. The number of asthmatics in the popula-
tion was estimated by multiplying the asthma prevalence 
among people of working age in the survey sample with 
the number of people of working age (the population size) 
estimated by using the weight of the sample. Because in 
CCHS data, the total disability days were for a two-week 
period, the one-year results were estimated by multiplying 
the two-weeks with 365/14.
The total disability days included the in-bed days (patients 
had to stay in bed) and the activity-restricted days. The pro-
portions of these among the total disability days were based 
on the information about whether or not the respondents had 
the in-bed days or the activity-restricted days in the CCHS 
dataset. We assumed that on the in-bed days patients could 
not go to work, and on the activity-restricted days patients 
could work with a reduction in functional level.
Accordingly, the number of productivity loss days was 
a sum between the number of in-bed days (absenteeism) 
and the number of activity-restricted days multiplied by a 
reduction in functional level (presenteeism), adjusted for 
ﬁ  ve working days per week, and for labor participation rate, 
which was 73% in Alberta in 2005.11
Regarding the reduction in functional level during 
restricted days of asthma patients, some previous Canadian 
studies used an arbitrary weight. For example, Krahn and 
colleagues6 used a weight of 0.5. However, by surveying 
892 adult asthma outpatients in southern Ontario, Ungar and 
colleagues12 suggested that a weight from 0.2 to 0.3 would 
more accurately reﬂ  ect restricted productivity loss days of 
asthma patients. Accordingly, these reductions in functional 
level were used for our analyses.
Using the human capital approach,13,14 cost of productivity 
losses were estimated by multiplying the number of produc-
tivity loss days with the average wage per day in Alberta, 
which was $158 in 2005.11
In summary, absenteeism was in-bed days and presentee-
ism was restricted days multiplied by reduction in functional 
level (20%–30%). The number of productivity loss days was 
found by adding absenteeism and presenteeism data and 
multiplying by ﬁ  ve working days per week (5/7) and by labor 
participation rate (73%). Therefore, the cost of productivity 
loss days was number of productivity loss days multiplied 
by average wage ($158).
A sensitivity analysis was performed for lower and upper 
boundaries of 95% conﬁ  dence interval (CI) of the difference 
in means of total disability days between asthmatics and 
nonasthmatics, and for lower and upper boundaries of the 
reduction in functional level.
Any productivity losses from job change or premature 
death were excluded from this study. Stata 9.2 (Stata Corp., 
College Station, TX) was used for data analyses.Journal of Asthma and Allergy 2009:2 45
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Results
In total, there were 11,800 people aged 12 and older in 
the survey. Of this sample, 8,522 people were from 18 to 
64 years old. Excluding three people who answered “don’t 
know” and one person who answered “not stated” for 
the question of asthma, we included 8.518 people. The 
prevalence of asthma among these people was estimated at 
8.5%. The sample was representative for a population size 
of 2,087,659.
Effects of asthma on the total disability 
days
Table 2 shows a multiple linear regression model examin-
ing inﬂ  uences of demographic characteristics and health 
conditions on the total two-week disability days of people. 
Controlling for other factors, the model showed that asthma 
signiﬁ  cantly increased the disability days (P  0.001). 
The difference in the means of two-week disability days 
between asthmatics and nonasthmatics was 0.487 (95% 
CI 0.286–0.688).
The other results shown by the model were also explain-
able and expected. For example, people with allergy, other 
chronic conditions, injury, poor health, hospitalization, 
and smoke had more disability days. Regarding sociode-
mographics, male, married, having a job last week, and 
people aged 60–64 years old had less while the poor had 
more disability days than otherwise. All the differences 
were statistically signiﬁ  cant.
Table 1 List of variables studied
Name Explanation % of asthmatics % of nonasthmatics
(N = 723) (N = 7795)
Outcome variable
Disability day Total two-week disability days
Main studied variable
Asthma Self-reported having an asthma diagnosis 100.0 0.0
Other health conditions
Allergy Self-reported having an allergy diagnosis 66.8 28.0
Smoke Self-reported having smoked 100 or more 
cigarettes
53.0 53.5
Injury Self-reported having at least one injury last year 30.2 23.5
Hospitalization Self-reported having at least one hospitalization 
last year
11.9 8.4
Poor health Self-perceived health as poor 5.1 2.1
Other, chronic Self-reported having at least another chronic 
condition (other than allergy)
21.4 36.5
Sociodemographic characteristics
Male Sex 38.6 48.8
Age group 1 18–19 years old 6.2 4.4
Age group 2 20–24 years old 12.9 9.9
Age group 3 25–29 years old 13.7 12.2
Age group 4 30–34 years old 12.5 11.9
Age group 5 35–39 years old 11.3 11.3
Age group 6 40–44 years old 7.9 12.0
Age group 7 45–49 years old 8.9 10.0
Age group 8 50–54 years old 9.7 10.8
Age group 9 55–59 years old 8.9 9.6
Age group 10 60–64 years old (used as the reference in the 
model)
8.2 8.0
Married Marital status 41.9 50.0
Job Had a job last week 78.7 79.2
Poor Household income is less than $15,000 6.1 5.1Journal of Asthma and Allergy 2009:2 46
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Asthma-related disability days
We considered the difference in the means of total disability 
days between asthmatics and nonasthmatics as asthma-
related disability days. By multiplying the two-week results 
with 365/14, asthma-related disability days per patient per 
year were estimated at 12.7 (7.5–17.9) (Table 3).
Table 3 also showed that the total asthma-related dis-
ability days and total asthma-related disability working 
days among Alberta’s labor force were about 1.6 million 
and 1.2 million in 2005, respectively. Of these, the in-bed 
days accounted for 22% and the restricted days accounted 
for 78%.
Asthma-related productivity losses 
for Alberta
Table 4 shows the number and costs of asthma-related 
productivity loss days by lower and upper boundaries of the 
total asthma-related disability working days; as well as by 
lower and upper boundaries of the reduction in functional 
level, in Alberta in 2005. With the reduction in functional 
level of 20%–30%, number of asthma-related productiv-
ity loss days was estimated at from 442 (259–624) to 533 
(313–753) thousand, respectively. The corresponding cost 
was from $70 ($41–$99) to $84 ($49–$119) million. Of these, 
the presenteeism accounted for 42%–52%.
Discussion
The indirect cost due to asthma-related productivity losses in 
Alberta was from $70 to $84 million in 2005. In combination 
with the direct cost (∼$65 million),8 asthma costs Alberta’s 
economy from 135 to 149 million a year in terms of both 
direct and indirect cost. Of this, the indirect cost accounts for 
52%–56%. This is comparable to results from other studies, 
such as a study by Ungar7 in southern Ontario in 1995 where 
the indirect costs of asthma estimated to account for 50% of 
the total, or the Economic Burden of Illness in Canada 1998 by 
Health Canada,5 where the indirect costs of asthma, bronchitis 
and emphysema were estimated to account for 53% of the total 
costs of these three diseases. Also in this report, indirect costs 
due to asthma morbidity were $679 million in 1998 or $835 
million in 2005 (based on a discount rate of 3%). It is reasonable 
to expect Alberta’s cost to be around one tenth of the national 
ﬁ  gure and thereby comparable to our estimates.
The productivity loss days per person per year, which 
averaged from ﬁ  ve to six corresponding to the reduction in 
functional level of 20%–30% in this study, are lower than 
the annual productivity loss days per person in Ungar and 
colleagues’ study,12 which were 11–12 for employees. This 
difference is to some extent because Ungar and colleagues 
included travel time, and waiting and treatment time in their 
calculation.12
Table 2 Multiple linear regression of the two-week disability days
Variables Coefﬁ  cient P value 95% Conﬁ  dence 
interval
Asthma 0.487 0.000 0.286 0.688
Allergy 0.446 0.000 0.309 0.583
Smoke 0.176 0.002 0.065 0.287
Injury 0.791 0.000 0.663 0.919
Hospitalization 1.184 0.000 0.989 1.379
Poor health 3.360 0.000 2.992 3.729
Other, chronic 0.380 0.000 0.244 0.517
Male −0.254 0.000 −0.365 −0.143
Age group 1 0.566 0.001 0.235 0.897
Age group 2 0.378 0.006 0.110 0.645
Age group 3 0.233 0.071 −0.020 0.485
Age group 4 0.362 0.005 0.110 0.613
Age group 5 0.326 0.012 0.072 0.579
Age group 6 0.378 0.003 0.126 0.630
Age group 7 0.483 0.000 0.223 0.743
Age group 8 0.533 0.000 0.278 0.787
Age group 9 0.439 0.001 0.180 0.698
Married −0.170 0.005 −0.289 −0.050
Job −0.305 0.000 −0.447 −0.163
Poor 0.428 0.001 0.176 0.681
Constant 0.197 0.138 −0.064 0.457
Notes: N = 8518; R-squared = 0.115; P = 0.000.
Table 3 Total asthma-related disability working days of labor force in Alberta, 2005
Total disability days per subject Of the labor force in one year
Two-week 
(I)
One-year 
(II)
Total disability 
days (III)
Total disability 
working days (IV)
Mean 0.487 12.7 1,644,732 1,174,809
Lower* 0.286 7.5 965,900 689,929
Upper* 0.688 17.9 2,323,564 1,659,688
Notes: *Corresponding to the lower and upper bounds of 95% CI of the mean; II = I * (365/14); III = II * 2,087,659 * 8.5% * 73%; IV = III * (5/7).Journal of Asthma and Allergy 2009:2 47
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Regarding the role of presenteeism in the productivity 
losses, our results showed that the presenteeism accounted 
for 42%–52% of the total. This is signiﬁ  cant but still 
lower than in the Lamb and colleagues study,15 where 
the presenteeism accounted for 68%. The difference is 
probably because Lamb and colleagues used a different 
reduction in functional level. The reduction in functional 
level (20%–30%) used in our study is suggested by Ungar 
and colleagues who developed a method to measure 
restricted days and to quantify total productivity loss days 
in adult asthma patients published in the Journal of Health 
Economics in 2000.12 If we calculate productivity loss 
days due to presenteeism per person per year, it will be 
about 2–3 days in the present study. This is comparable to 
allergy-related productivity loss days due to presenteeism 
per person per year reported by Stevens in a Chicago-based 
BankOne survey.16
A limitation in this study is that the two-week disability 
days were generalized to one year. One may argue that there 
is a bias due to seasonal effects. However, the 2005 CCHS 
was designed to control for seasonal effects by allocating 
the data collection equally throughout 12 months of the sur-
veyed year, and by applying an adjustment in the weighting 
to ensure that the portion of the sample interviewed each 
season represented 25% of the total population.10 Therefore, 
we believe that the seasonal effect is minimal. Furthermore, 
a two-week recall period used for disability days would be 
less recall-biased in comparison with a longer one (such as 
one year). Another limitation is that asthmatic mortality is not 
included in the analysis. This may result in an underestima-
tion of the total indirect costs. However, the indirect costs 
incurred by premature deaths of asthma are small since the 
asthmatic mortality rate is low in Alberta. In 2005, there 
were only 16 cases of death, equivalent to the rate of 0.5 per 
100,000 people.8
In conclusion, the number of asthma-related productiv-
ity loss days in Alberta in 2005 was from 442 (259–624) 
to 533 (313–753) thousand. The corresponding cost was 
from $70 ($41–$99) to $84 ($49–$119) million. Of these, 
presenteeism accounted for 42%–52%. These results sug-
gest that an improvement in controlling asthma could have a 
signiﬁ  cant economic impact in Alberta, and that presentee-
ism plays an important role in asthma-related productivity 
losses. Therefore employers should not only pay attention 
to absenteeism, but also to presenteeism to minimize pro-
ductivity loss.
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